[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","g0t1qwq1tik6prvoqoxlf3cbe","revision",2,"title","Alterity Therapeutics Limited 提交 6-K 文件","originalTitle","6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)","summary","Alterity Therapeutics Limited 提交 6-K 文件，披露管理层雇佣条款变更。文件包含公司注册信息及签署人信息，未提及具体产品或财务数据。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-21T10:00:53.000Z","discoveredAt","2026-10-21T11:36:29.716Z","timelineAt","category","tip","tags",[80,81,82],"stockSymbols",[79],"score",23,"selected",false,"channel","news","story",{"_71":72,"_15":73},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":14,"_68":69,"_70":69},"hasTranslation","bodyLanguage","original","factId","fua-CShZiPDg",{"_71":72,"_15":73},"reportCount","additionalSourceCount",0,"developmentCount","publicId","3fbe9487-a153-41d2-a797-798eb942854a","Mesoblast Limited 2026年提交多份文件",{"_71":72,"_15":73},"zh","

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

99.1

\n\t\t\t

Changes to Managing Director Terms of Employment

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

	\n\t\t\t Alterity Therapeutics Limited \n\t\t\t

	\n\t\t\t By: \n\t\t\t	\n\t\t\t /s/ Julian Babarczy \n\t\t\t
		\n\t\t\t Julian Babarczy \n\t\t\t
		\n\t\t\t Chairman \n\t\t\t

Date: October 21, 2026

","zhKind","complete","ATHE","政策与监管","退市","停复牌","aihot","/items/g0t1qwq1tik6prvoqoxlf3cbe","https://www.sec.gov/Archives/edgar/data/1131343/000143774926033045/0001437749-26-033045-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792800000&sig=a1281a539589308a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792800000&sig=57a86ea6a382db0f 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792800000&sig=f9807010575fb678 96w","changelogVersion","2026-10-01T08:00"]